Liquid biopsy in non-small cell lung cancer-current status and future outlook-a narrative review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34164273/
Lung cancer ranks first as the cause of cancer-associated deaths gobally. The American Cancer Society estimates for 228,820 new cases and 135,720 deaths from lung cancer in the United States...
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Points • The current literature review covers NSCLC liquid biopsy and the advantages/disadvantages of different approaches. • The authors noted that liquid biopsy is uncommonly used, although its popularity is increasing. Show More
Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34164187/
Background: EGFR-mutated lung cancer poorly responded to anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy. Whether patients with EGFR-mutated lung cancer can benefit from anti-PD-1/PD-L1 therapy combined with other drugs remains...
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Points • In the current study, researchers retrospectively assessed whether 56 patients with EGFR-mutated lung cancer were effectively be treated with PD-1/PD-L1 therapy plus chemotherapy with or without bevacizumab. These Show More
A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34166445/
For profiling clinical plasma samples, characterized by low ctDNA abundance, the SensiScreen® EGFR Liquid assay is able to identify down to 1 copy of mutant alleles and with its high...
p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34164404/
Bruton's tyrosine kinase (BTK) is a non-receptor intracellular kinase playing a key role in the proliferation and survival of normal and malignant B-lymphocytes. Its targeting by Ibrutinib, the first specific...
Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34154791/
Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib